Protalix BioTherapeutics
Protalix BioTherapeutics, a pioneering biopharmaceutical company headquartered in Israel, focuses on developing and commercialising innovative therapies for rare diseases. Founded in 2003, Protalix has made significant strides in the biotechnology sector, particularly in the production of therapeutic proteins using its proprietary plant cell-based expression system. The company’s flagship product, Elelyso, is a unique enzyme replacement therapy for Gaucher disease, showcasing Protalix's commitment to addressing unmet medical needs. With a strong emphasis on research and development, Protalix BioTherapeutics has positioned itself as a leader in the biopharmaceutical industry, achieving notable milestones in regulatory approvals and partnerships. Its operational reach extends beyond Israel, impacting patients globally with its cutting-edge therapies.
DitchCarbon Score
How does Protalix BioTherapeutics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Protalix BioTherapeutics's score of 3 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Protalix BioTherapeutics's reported carbon emissions
Protalix BioTherapeutics, headquartered in Israel (IL), currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions data, it is challenging to assess their carbon footprint or climate commitments accurately. However, the company may be engaged in various initiatives to address climate change, as is common in the biopharmaceutical industry. Many companies in this sector are increasingly focusing on sustainability and reducing their environmental impact. Protalix BioTherapeutics may also be exploring strategies to align with industry standards for carbon reduction, although specific details are not provided.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Protalix BioTherapeutics is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
